{"id":131845,"date":"2022-08-01T09:37:27","date_gmt":"2022-08-01T13:37:27","guid":{"rendered":"https:\/\/44.250.171.167\/?p=131845"},"modified":"2022-10-06T04:55:09","modified_gmt":"2022-10-06T08:55:09","slug":"torrent-pharmaceuticals-ltd-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Torrent Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Torrent Pharmaceuticals Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/TORNTPHARM\/\">TORNTPHARM<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>TORNTPHARM launched four products in 1Q23 and will be launching 4 products in 2Q23, of which three are expected to be day-one launches.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Tushar Manudhane of Motilal Oswal asked about shortage of medicine in Germany market, if it\u2019s a temporary shortage or if there is good opportunity. Sanjay Gupta ED replied that the company has not seen any impact of any shortages in Germany. On the contrary, the company saw Germany govt. review reference prices.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal with Axis Capital asked about the INR38 crore settlement income, where it is included. Sudhir Menon CFO replied that it\u2019s in other operating income. It\u2019s related to patent settlement that\u2019s done with one of the innovator which is non-recurring.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal with Axis Capital asked about the current capacity utilization. \u00a0Sudhir Menon CFO answered that all the facilities put together, the company should be around 54% capacity utilization.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal with Axis Capital enquired if there is any expectation of US FDA resolution by end of 2022. Sudhir Menon CFO clarified that with the internal understanding, the minimum expectation is that it should happen over the next 3-4 months.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Agarwal with Axis Capital asked about the volume and price breakup of India growth. Sudhir Menon CFO replied that the company\u2019s AIOCD growth reflection is 17% and breakup is volume at 5%, price at 9% and new products at 3%.<\/li>\n<\/ul>\n<ul>\n<li>Dheeresh Pathak from White Oak Capital asked about the share of top brands in Brazil. \u00a0Sudhir Menon CFO said it\u2019s a specialty business. About 83% of the prescriptions are generated from specialties. The company added that 88% of company\u2019s business is coming from brands above 20 million reais, which is 10.<\/li>\n<\/ul>\n<ul>\n<li>Damayanti Kerai from HSBC asked about the outlook for growth in the Brazil segment. Sudhir Menon CFO said that in the last 6 months, the company launched 5 products in Brazil, which is the result of large number of filing and approvals in Brazil. Currently, the company has 11 products that are under approval.<\/li>\n<\/ul>\n<ul>\n<li>Saion Mukherjee of Nomura enquired that in Brazil, how much market TORNTPHARM currently covers. Sudhir Menon CFO answered that the coverage is currently around 22-23% and the company is aiming to double it in the next 3 years.<\/li>\n<\/ul>\n<ul>\n<li>Saion Mukherjee of Nomura also asked about the size of the branded market; CNS, diabetes, cardio in Brazil and the company\u2019s position in the 3 segments. Sudhir Menon CFO replied that the overall branded generic market is about $20 million and the covered market is going currently around 5% and TORNTPHARM\u2019s growth in this area is about 13.7%.<\/li>\n<\/ul>\n<ul>\n<li>Kartik Mehta from Klay Capital asked about the India business, if there are lesser opportunities of larger size due to issues of valuation or product mix. Sudhir Menon CFO answered that inorganic remains the core focus for the company. TORNTPHARM also added that it\u2019s not about size but the strategic fit.<\/li>\n<\/ul>\n<ul>\n<li>Nitin Agarwal from DAM Capital asked about the US plants operating at 54% capacity utilization, if there is any element of underrecovery. \u00a0Sudhir Menon CFO clarified that all the facilities in India put together the capacity utilization is 54% and not for only US facilities. There are no under absorbed overheads in the P&amp;L.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY23 Earnings Concall Management Update: TORNTPHARM launched four products in 1Q23 and will be launching 4 products in 2Q23, of which three are expected to be day-one launches. Q&amp;A Highlights: Tushar Manudhane of Motilal Oswal asked about shortage of medicine in Germany market, if it\u2019s a temporary [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Torrent Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights #TORNTPHARM #Q1 #FY23","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-131845","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":135122,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131845,"position":0},"title":"Torrent Pharmaceuticals Ltd Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"October 25, 2022","format":false,"excerpt":"Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q2 FY23 Earnings Concall \u00a0Q&A Highlights: [00:06:41]Damayanti Kerai from HSBC asked about split of India business growth in 2Q in terms of \u00a0price, volume and new launches. Sudhir Menon CFO replied that the company had 19% growth and the breakup of 19% is\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139387,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131845,"position":1},"title":"Torrent Pharmaceuticals Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"January 27, 2023","format":false,"excerpt":"Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3 FY23 Earnings Concall Management Update: [00:05:39] TORNTPHARM said the company expects to file about 5-6 products in FY23. Q&A Highlights: [00:06:50] Saion Mukherjee of Nomura Securities asked about the organic growth without Curatio. Sudhir Menon CFO replied that the base business growth\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":130197,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":131845,"position":2},"title":"Torrent Pharmaceuticals Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 26, 2022","format":false,"excerpt":"Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q4 FY22 Earnings Concall Q&A Highlights: Anubhav Aggarwal of Credit Suisse asked about Brazil market, how much the five launches the company did in 4Q22 contributed as a percentage of sales. Sanjay Gupta ED said the company showed a growth of about 21%\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":166613,"url":"https:\/\/alphastreet.com\/india\/torntpharm-q3-2024-2025-call-highlights-margins-surge-india-growth-insulin-recovery\/","url_meta":{"origin":131845,"position":3},"title":"TORNTPHARM Q3 2024-2025 Call Highlights: Margins Surge, India Growth, &#038; Insulin Recovery!","author":"Praveen","date":"January 29, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd., a leading pharma company in India, in its Q3 earnings call addressed that it expects to maintain a 32.5% margin in Q4, with annual improvements of 50-100 basis points, while its insulin CMO business anticipates significant spillover beyond the normal quarterly run rate. In India, the company\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":155267,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":131845,"position":4},"title":"Torrent Pharmaceuticals Ltd Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"October 24, 2023","format":false,"excerpt":"Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q2 FY24 Earnings Concall Revenue Growth Across Key Markets India business revenue grew 18% year-on-year; 12% growth excluding Curatio acquisition. Strong constant currency revenue growth of 8% in Germany and 23% in Brazil. US revenues declined due to loss of low-margin business and\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":131835,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":131845,"position":5},"title":"Sun Pharmaceutical Industries Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 1, 2022","format":false,"excerpt":"Key highlights from Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY23 Earnings Concall Management Update: SUNPHARMA recorded the highest ever quarterly revenue in 1Q23, with sales increasing 14% YonY, excluding the contribution of 1Q22. SUNPHARMA\u2019s current generic pipeline for the US includes 89 ANDAs and 13 NDAs awaiting approval with the\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/131845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=131845"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/131845\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=131845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=131845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=131845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}